SE9600071D0 - New oral formulation of two active ingredients I - Google Patents

New oral formulation of two active ingredients I

Info

Publication number
SE9600071D0
SE9600071D0 SE9600071A SE9600071A SE9600071D0 SE 9600071 D0 SE9600071 D0 SE 9600071D0 SE 9600071 A SE9600071 A SE 9600071A SE 9600071 A SE9600071 A SE 9600071A SE 9600071 D0 SE9600071 D0 SE 9600071D0
Authority
SE
Sweden
Prior art keywords
proton pump
pump inhibitor
active ingredients
oral formulation
fixed formulation
Prior art date
Application number
SE9600071A
Other languages
English (en)
Swedish (sv)
Inventor
Helene Depui
Agneta Hallgren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20400969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9600071(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9600071A priority Critical patent/SE9600071D0/xx
Publication of SE9600071D0 publication Critical patent/SE9600071D0/xx
Priority to BRPI9607350-0A priority patent/BR9607350B1/pt
Priority to PL96322175A priority patent/PL187075B1/pl
Priority to PT96944726T priority patent/PT813424E/pt
Priority to ES96944726T priority patent/ES2185817T5/es
Priority to AT96944726T priority patent/ATE228009T1/de
Priority to EP96944726A priority patent/EP0813424B2/en
Priority to CN96193594A priority patent/CN1080125C/zh
Priority to CA002213996A priority patent/CA2213996C/en
Priority to HU9904024A priority patent/HU229153B1/hu
Priority to DE69624907T priority patent/DE69624907T3/de
Priority to DK96944726T priority patent/DK0813424T4/da
Priority to MX9706785A priority patent/MX9706785A/es
Priority to AU13241/97A priority patent/AU712669B2/en
Priority to JP9525131A priority patent/JPH11501950A/ja
Priority to NZ325977A priority patent/NZ325977A/xx
Priority to KR1019970706236A priority patent/KR100490075B1/ko
Priority to US08/750,934 priority patent/US6183776B1/en
Priority to SK1169-97A priority patent/SK283695B6/sk
Priority to TR97/00916T priority patent/TR199700916T1/xx
Priority to RU97116726/14A priority patent/RU2179453C2/ru
Priority to CZ19972747A priority patent/CZ293583B6/cs
Priority to EE9700192A priority patent/EE04002B1/xx
Priority to PCT/SE1996/001737 priority patent/WO1997025066A1/en
Priority to UA97104949A priority patent/UA45392C2/uk
Priority to IL12165196A priority patent/IL121651A/xx
Priority to ARP960105899A priority patent/AR005281A1/es
Priority to TW085116139A priority patent/TW464514B/zh
Priority to ZA9610935A priority patent/ZA9610935B/xx
Priority to MYPI97000065A priority patent/MY116091A/en
Priority to EG1897A priority patent/EG23821A/xx
Priority to SA97170553A priority patent/SA97170553B1/ar
Priority to IS4548A priority patent/IS2716B/is
Priority to NO19974071A priority patent/NO326656B1/no
Priority to HK98100847A priority patent/HK1001763A1/xx
Priority to HK98111792A priority patent/HK1017992A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9600071A 1996-01-08 1996-01-08 New oral formulation of two active ingredients I SE9600071D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I
UA97104949A UA45392C2 (uk) 1996-01-08 1996-12-20 Пероральна фармацевтична лікарська форма, що містить інгібітор протонного насоса і антацидні речовини або альгінати, спосіб одержання дозованої лікарської форми (варіанти) та спосіб лікування розладів, пов'язаних з диспепсією
IL12165196A IL121651A (en) 1996-01-08 1996-12-20 Multiple unit tableted dosage form comprising a proton pump inhibitor and antacid(s) or alginate(s)
NZ325977A NZ325977A (en) 1996-01-08 1996-12-20 Composition comprising an enteric coated proton pump inhibitor and an antacid agent or alginate
SK1169-97A SK283695B6 (sk) 1996-01-08 1996-12-20 Viaczložková tabletová lieková forma, spôsob jej prípravy a jej použitie
PT96944726T PT813424E (pt) 1996-01-08 1996-12-20 Formas de dosagem farmaceutica oral que contem um inibidor da bomba de protoes e um agente antacido ou alginato
ES96944726T ES2185817T5 (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica oral que comprenden un inhibidor de las bombas de protones y un agente antiacido o alginato.
AT96944726T ATE228009T1 (de) 1996-01-08 1996-12-20 Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten
EP96944726A EP0813424B2 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
CN96193594A CN1080125C (zh) 1996-01-08 1996-12-20 含有质子泵抑制剂和抗酸剂或藻酸盐的口服药物剂型
CA002213996A CA2213996C (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
HU9904024A HU229153B1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
DE69624907T DE69624907T3 (de) 1996-01-08 1996-12-20 Orale, pharmazeutische darreichungsformen, die einen protonenpumpeninhibitor und ein antacidum oder alginat enthalten
DK96944726T DK0813424T4 (da) 1996-01-08 1996-12-20 Orale farmaceutiske doseringsformer omfattende en protonpumpeinhibitor og et syreneutraliserende middel eller alginat
MX9706785A MX9706785A (es) 1996-01-08 1996-12-20 Formas de dosificacion farmaceutica oral que comprenden un inhibidor de la bomba de protones y un agente antiacido o alginato.
AU13241/97A AU712669B2 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
JP9525131A JPH11501950A (ja) 1996-01-08 1996-12-20 プロトンポンプ抑制剤および制酸剤またはアルギネートを含有する経口用医薬剤形
BRPI9607350-0A BR9607350B1 (pt) 1996-01-08 1996-12-20 forma de dosagem em tablete unitário múltiplo.
KR1019970706236A KR100490075B1 (ko) 1996-01-08 1996-12-20 양성자펌프억제제및제산제또는알기네이트함유경구제약제형
US08/750,934 US6183776B1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
PL96322175A PL187075B1 (pl) 1996-01-08 1996-12-20 Farmaceutyczna postać dawkowana, sposób wytwarzania doustnej farmaceutycznej postaci dawkowanej i zastosowanie farmaceutycznej postaci dawkowanej
TR97/00916T TR199700916T1 (xx) 1996-01-08 1996-12-20 Oral ispen�iyari dozaj formlar�.
RU97116726/14A RU2179453C2 (ru) 1996-01-08 1996-12-20 Пероральные фармацевтические лекарственные формы, включающие ингибитор протонного насоса и антацидное вещество или альгинат
CZ19972747A CZ293583B6 (cs) 1996-01-08 1996-12-20 Vícesložková tabletová orální farmaceutická dávková forma, způsob její výroby a použití
EE9700192A EE04002B1 (et) 1996-01-08 1996-12-20 Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
PCT/SE1996/001737 WO1997025066A1 (en) 1996-01-08 1996-12-20 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
ARP960105899A AR005281A1 (es) 1996-01-08 1996-12-26 Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
TW085116139A TW464514B (en) 1996-01-08 1996-12-27 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
ZA9610935A ZA9610935B (en) 1996-01-08 1996-12-30 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
MYPI97000065A MY116091A (en) 1996-01-08 1997-01-07 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
EG1897A EG23821A (en) 1996-01-08 1997-01-07 Oral pharmaceutical dosage forms comprising a protom pump inhibitor and an antacid agent or alginate
SA97170553A SA97170553B1 (ar) 1996-01-08 1997-01-15 اشكال معايرة جرعات صيدلانية تعطى بالفم تتضمن مثبط مضخة البروتون proton pump inhibitor وعامل مضاد للحموضة او الجينات alginate
IS4548A IS2716B (is) 1996-01-08 1997-08-20 Lyfjaform til inntöku sem samanstendur af prótónpumpuhemli og sýrubindandi lyfi eða algínati
NO19974071A NO326656B1 (no) 1996-01-08 1997-09-04 Orale, farmasoytiske doseringsformer innbefattende en protonpumpeinhibitor og et syrenoytraliserende middel eller alginat, fremgangsmate for fremstilling av slike doseringsformer og anvendelse derav.
HK98100847A HK1001763A1 (en) 1996-01-08 1998-02-05 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
HK98111792A HK1017992A1 (en) 1996-01-08 1998-11-06 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I

Publications (1)

Publication Number Publication Date
SE9600071D0 true SE9600071D0 (sv) 1996-01-08

Family

ID=20400969

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600071A SE9600071D0 (sv) 1996-01-08 1996-01-08 New oral formulation of two active ingredients I

Country Status (35)

Country Link
US (1) US6183776B1 (is)
EP (1) EP0813424B2 (is)
JP (1) JPH11501950A (is)
KR (1) KR100490075B1 (is)
CN (1) CN1080125C (is)
AR (1) AR005281A1 (is)
AT (1) ATE228009T1 (is)
AU (1) AU712669B2 (is)
BR (1) BR9607350B1 (is)
CA (1) CA2213996C (is)
CZ (1) CZ293583B6 (is)
DE (1) DE69624907T3 (is)
DK (1) DK0813424T4 (is)
EE (1) EE04002B1 (is)
EG (1) EG23821A (is)
ES (1) ES2185817T5 (is)
HK (2) HK1001763A1 (is)
HU (1) HU229153B1 (is)
IL (1) IL121651A (is)
IS (1) IS2716B (is)
MX (1) MX9706785A (is)
MY (1) MY116091A (is)
NO (1) NO326656B1 (is)
NZ (1) NZ325977A (is)
PL (1) PL187075B1 (is)
PT (1) PT813424E (is)
RU (1) RU2179453C2 (is)
SA (1) SA97170553B1 (is)
SE (1) SE9600071D0 (is)
SK (1) SK283695B6 (is)
TR (1) TR199700916T1 (is)
TW (1) TW464514B (is)
UA (1) UA45392C2 (is)
WO (1) WO1997025066A1 (is)
ZA (1) ZA9610935B (is)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US8071128B2 (en) * 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1998023272A1 (en) * 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders
MX9703918A (es) * 1997-05-28 1998-11-30 J Marshall M D Barry Procedimiento para preparar un producto farmaceutico reactivo para deteccion de desorden gastrointestinal causado por bacteria en el tracto gastrointestinal superior.
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
WO1999029299A1 (en) * 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel suppository form comprising an acid-labile active compound
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774906B1 (fr) * 1998-02-13 2000-05-12 Rhodia Chimie Sa Systeme d'encapsulation a coeur organique et a ecorce minerale a base d'hydroxycarbonate d'aluminium et son procede de preparation
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
DK1561458T3 (da) 1998-07-28 2010-10-25 Takeda Pharmaceutical Hurtigt henfaldende fast middel
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
MXPA01009934A (es) * 1999-03-29 2002-06-21 American Home Prod Sistema de recubrimiento.
WO2001003707A1 (en) * 1999-07-12 2001-01-18 Smithkline Beecham Corporation Heartburn treatment
CA2387746C (en) 1999-10-20 2010-06-29 Koji Ukai Methods for stabilizing benzimidazole-based compounds
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
KR20040018463A (ko) * 2001-07-16 2004-03-03 아스트라제네카 아베 양성자 펌프 억제제 및 제산제를 함유하는 제약 제제
AR036354A1 (es) * 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida
US20040213848A1 (en) * 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7008777B2 (en) 2001-10-15 2006-03-07 Barry J. Marshall System for the detection of urease and method for using same
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
KR100479637B1 (ko) * 2002-02-01 2005-03-31 한국화학연구원 란소프라졸을 함유하는 경구제제 및 그의 제조방법
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US6663892B1 (en) * 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (en) * 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Stable solid preparations
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US7258981B2 (en) * 2003-01-24 2007-08-21 Clontech Laboratories, Inc. Sensitive proteasome sensor constructs and methods for their design and use
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
EP1759692A3 (en) * 2003-03-10 2007-09-12 Novartis AG Taste-masked solid veterinary compositions
KR101173580B1 (ko) * 2003-03-18 2012-08-13 코와 가부시키가이샤 제산제 조성물
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
US7282050B2 (en) * 2003-10-31 2007-10-16 Medtronic, Inc. Ablation of exterior of stomach to treat obesity
US7252665B2 (en) * 2003-10-31 2007-08-07 Medtronic, Inc Ablation of stomach lining to reduce stomach acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US7041124B2 (en) * 2003-12-23 2006-05-09 Kimberly-Clark Worldwide, Inc. System and method for providing therapy to a portion of a body
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
SE530605C2 (sv) * 2005-09-29 2008-07-15 Barbara Nelson Läkemedel innehållande ett syrahämmande medel, avseende att användas för att motverka och bota luftvägssjukdomar
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
AR056062A1 (es) 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
CN101120930B (zh) * 2006-08-11 2010-09-29 石药集团中奇制药技术（石家庄）有限公司 一种奥美拉唑组合物及其制备方法
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN101259140B (zh) * 2007-03-08 2012-08-22 重庆北碚现代应用药物研究所 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法
ES2759626T3 (es) * 2007-05-07 2020-05-11 Evonik Operations Gmbh Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
ITFI20070253A1 (it) * 2007-11-09 2009-05-10 Valpharma Internat S P A Formulazioni farmaceutiche per la somministrazione di ipp.
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010038241A2 (en) * 2008-09-30 2010-04-08 Panacea Biotec Limited Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
CA2766524A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
TW201127375A (en) * 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
BR112012026860A2 (pt) 2010-04-23 2018-06-05 S Biotek Holding Aps composição farmacêutica sólida para neutralizar ácido estomacal
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US20150238514A1 (en) * 2014-02-21 2015-08-27 William Armstrong Protective Supplement Configuration
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2016404808A1 (en) * 2016-04-29 2018-12-13 Alan Thompson Veterinary composition
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TR201723199A2 (tr) * 2017-12-30 2019-07-22 Neutec Ar Ge Sanayi Ve Ticaret Anonim Sirketi Yeni farmasötik bileşimler.
KR102006777B1 (ko) * 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) * 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
JP2021533177A (ja) * 2018-08-23 2021-12-02 チョン クン ダン ファーマシューティカル コーポレイション エソメプラゾール及び炭酸水素ナトリウムを含む、優れた溶解特性を備えた薬学的製剤
MX2022004464A (es) * 2019-10-17 2022-05-03 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de la bomba de protones y un antiacido.
MX2022009121A (es) * 2020-01-23 2022-08-18 Hanmi Pharm Ind Co Ltd Formulacion farmaceutica compuesta que comprende un inhibidor de la bomba de protones y un antiacido.
EP4070789A4 (en) * 2020-01-23 2024-01-24 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITE FORMULATION WITH PROTON PUMP INHIBITOR AND ANTACID
KR102608889B1 (ko) * 2020-07-14 2023-12-04 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
KR20220065997A (ko) * 2020-11-13 2022-05-23 (주)휴온스 라베프라졸 및 제산제를 포함하는 약제학적 복합제제 및 이의 제조방법
CN114569579B (zh) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 肠溶微丸、其制备方法和包含它的制剂
KR20230097346A (ko) * 2021-12-24 2023-07-03 한미약품 주식회사 프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제
KR102553713B1 (ko) * 2022-11-18 2023-07-10 고덕상 미네랄 촉매제를 이용한 양식어류사료 제조방법

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
JPS5598120A (en) 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
US4377568A (en) 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
JPS5973529A (ja) 1982-10-12 1984-04-25 Sankyo Co Ltd 被覆固形製剤の製造法
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
US4518433A (en) 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
GB2132887A (en) 1982-11-15 1984-07-18 Procter & Gamble Enteric-coated anti-inflammatory compositions
US4556552A (en) 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0759499B2 (ja) 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤
US4568560A (en) 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
EP0250572A1 (en) 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
US5112813A (en) 1986-03-07 1992-05-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Process for the preparation of a viscosity-stable antacid composition
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DK179687D0 (da) 1987-04-08 1987-04-08 Farma Food As Praeparat
KR960011236B1 (ko) † 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
EP0294933B1 (en) † 1987-05-08 1992-03-11 Smith Kline & French Laboratories Limited Pharmaceutical compositions
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
BE1002406A5 (fr) 1988-09-20 1991-01-29 Glaxo Group Ltd Compositions pharmaceutiques.
SE8803822D0 (sv) * 1988-10-26 1988-10-26 Novel dosage form
US5026559A (en) † 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE4023028A1 (de) * 1990-07-20 1992-01-23 Hoechst Ag Ferroelektrische fluessigkristalline si-enthaltende copolymere, ein verfahren zu ihrer herstellung, mischungen dieser copolymere mit niedermolekularen fluessigkristallen und die verwendung in elektrooptischen bauteilen
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3142919B2 (ja) 1991-11-06 2001-03-07 旭化成株式会社 セルロース誘導体ラテックス及びその製法
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5229137A (en) † 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
US5447918A (en) 1992-07-27 1995-09-05 Mccullough; Ricky W. Gastrointestinal anti-irritant composition comprising sucralfate and methods of use
JPH07509702A (ja) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US5330759A (en) 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
CA2110313C (en) † 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
WO1995001795A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate-antacid combinations
AU7218294A (en) † 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
WO1995008332A1 (en) 1993-09-20 1995-03-30 The Procter & Gamble Company Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection
JP3017906B2 (ja) 1993-10-08 2000-03-13 信越化学工業株式会社 腸溶性コーティング剤分散液
US5798120A (en) † 1993-10-12 1998-08-25 Tokyo Tanabe Company Limited Enteric granule-containing tablets
GB2285989A (en) 1994-01-28 1995-08-02 Merck Frosst Canada Inc Aqueous formulations for enteric coatings
AUPM596894A0 (en) 1994-05-30 1994-06-23 Hybrid Scientific Pty Ltd Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
AUPM695294A0 (en) 1994-07-20 1994-08-11 Borody, Thomas Julius Improved combination therapy dose unit
EP0814773B1 (en) 1995-03-17 2001-07-25 The Boots Company PLC Pectin liquid pharmaceutical compositions
US5824339A (en) † 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1998023272A1 (en) 1996-11-27 1998-06-04 The Procter & Gamble Company Compositions and methods for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
PL187075B1 (pl) 2004-05-31
AU1324197A (en) 1997-08-01
EP0813424A1 (en) 1997-12-29
ES2185817T5 (es) 2009-11-24
PT813424E (pt) 2003-03-31
HUP9904024A2 (hu) 2000-05-28
DE69624907T2 (de) 2003-08-21
KR100490075B1 (ko) 2005-09-08
IL121651A0 (en) 1998-02-08
HK1017992A1 (en) 1999-12-10
JPH11501950A (ja) 1999-02-16
HU229153B1 (en) 2013-09-30
SA97170553B1 (ar) 2006-06-04
NZ325977A (en) 1999-02-25
BR9607350A (pt) 1997-12-30
UA45392C2 (uk) 2002-04-15
HK1001763A1 (en) 1998-07-10
NO974071L (no) 1997-10-17
ZA9610935B (en) 1997-07-08
ATE228009T1 (de) 2002-12-15
DK0813424T3 (da) 2003-03-10
HUP9904024A3 (en) 2002-03-28
CN1183047A (zh) 1998-05-27
NO974071D0 (no) 1997-09-04
CZ274797A3 (cs) 1998-03-18
ES2185817T3 (es) 2003-05-01
MY116091A (en) 2003-11-28
EP0813424B1 (en) 2002-11-20
PL322175A1 (en) 1998-01-19
CN1080125C (zh) 2002-03-06
WO1997025066A1 (en) 1997-07-17
SK116997A3 (en) 1998-05-06
AU712669B2 (en) 1999-11-11
CA2213996A1 (en) 1997-07-17
CA2213996C (en) 2006-08-29
IL121651A (en) 2003-05-29
KR19980702829A (ko) 1998-08-05
CZ293583B6 (cs) 2004-06-16
DK0813424T4 (da) 2009-11-09
IS4548A (is) 1997-08-20
EE9700192A (et) 1998-02-16
TW464514B (en) 2001-11-21
BR9607350B1 (pt) 2010-08-10
DE69624907D1 (de) 2003-01-02
TR199700916T1 (xx) 1997-12-21
NO326656B1 (no) 2009-01-26
EE04002B1 (et) 2003-04-15
AR005281A1 (es) 1999-04-28
EP0813424B2 (en) 2009-08-05
SK283695B6 (sk) 2003-12-02
RU2179453C2 (ru) 2002-02-20
IS2716B (is) 2011-02-15
DE69624907T3 (de) 2010-01-14
MX9706785A (es) 1997-11-29
EG23821A (en) 2007-09-19
US6183776B1 (en) 2001-02-06

Similar Documents

Publication Publication Date Title
SE9600071D0 (sv) New oral formulation of two active ingredients I
SE9600072D0 (sv) New oral formulation of two active ingredients II
SE9500422D0 (sv) New oral pharmaceutical dosage forms
MY119212A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
CA2214027A1 (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
ATE275396T1 (de) Aus mehreren einzeleinheiten zusammengesetztes pharmazeutisches präparat, das einen protonenpumpeninhibitor enthält
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
CY1112510T1 (el) Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο
DE60229295D1 (de) Komprimierte, orale pharmazeutische dosierungsform mit enterischer beschichtung, die eine säurelabile benzimidazolverbindung enthält
ATE251894T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung
WO2002069968A8 (en) New use
RU2001135704A (ru) Средство для лечения хронического воспаления, вызванного хронической сердечной недостаточностью
RU2000117903A (ru) Способ лечения хронического гастрита и язвенной болезни двенадцатиперстной кишки
JO1881B1 (en) Formula II for multi unit disc calibration